Vadadustat Patent Expiration
Vadadustat was first introduced by Akebia Therapeutics Inc
Vadadustat Patents
Given below is the list of patents protecting Vadadustat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vafseo | US11324734 | Compositions and methods for treating anemia | Mar 31, 2036 | Akebia |
| Vafseo | US11844756 | Compositions and methods for treating anemia | Mar 31, 2036 | Akebia |
| Vafseo | US10149842 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US11065237 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US9701636 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US9987262 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US11857543 | Compositions and methods for treating anemia | Jun 09, 2034 | Akebia |
| Vafseo | US8323671 | Prolyl hydroxylase inhibitors and methods of use | Apr 03, 2028 | Akebia |
| Vafseo | US7811595 | Prolyl hydroxylase inhibitors and methods of use | Mar 13, 2028 | Akebia |
| Vafseo | US8343952 | Prolyl hydroxylase inhibitors and methods of use | Aug 14, 2027 | Akebia |
| Vafseo | US8598210 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
| Vafseo | US8940773 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
| Vafseo | USRE47437 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vadadustat's patents.
Latest Legal Activities on Vadadustat's Patents
Given below is the list recent legal activities going on the following patents of Vadadustat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 11 Jun, 2024 | US8940773 |
| Patent eCofC Notification | 11 Jun, 2024 | US8940773 |
| Email Notification Critical | 11 Jun, 2024 | US8940773 |
| Recordation of Patent eCertificate of Correction | 11 Jun, 2024 | US8940773 |
| Initial letter Re: PTE Application to regulating agency | 21 May, 2024 | US8940773 |
| Post Issue Communication - Certificate of Correction | 21 May, 2024 | US8940773 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US8940773 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US7811595(Litigated) |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US8343952(Litigated) |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US8598210(Litigated) |
Vadadustat's Family Patents
